Literature DB >> 18395079

Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus.

Rahul Pannala1, Jeffery B Leirness, William R Bamlet, Ananda Basu, Gloria M Petersen, Suresh T Chari.   

Abstract

BACKGROUND & AIMS: Information on the clinical profile of pancreatic cancer (PaC) associated diabetes (DM) is limited. We compared the prevalence and clinical characteristics of DM in subjects with and without PaC.
METHODS: We prospectively recruited 512 newly diagnosed PaC cases and 933 controls of similar age, who completed demographic and clinical questionnaires and had fasting blood glucose (FBG) levels measured at recruitment and after pancreaticoduodenectomy (n = 105). Subjects with a FBG level >126 mg/dL or who were on antidiabetic treatment were classified as having DM.
RESULTS: DM was more prevalent (47% vs 7%; P < .001) and predominantly of new onset (<2-year duration) (74% vs 53%; P = .002) among cases compared with controls. Among PaC cases, those with DM (n = 243) were older (68 +/- 10 vs 64 +/- 12 years; P < .001), reported higher usual adult body mass index (30 +/- 6 vs 27 +/- 5 kg/m(2); P < .001), and had a greater frequency of family history of DM (47% vs 31%; P < .001) compared with those without DM (n = 269). After pancreaticoduodenectomy, while DM resolved in 17 of 30 patients (57%) with new-onset DM, its prevalence was unchanged in patients with long-standing DM (n = 11) (P = .009).
CONCLUSIONS: PaC is a powerful diabetogenic state; DM associated with PaC is often new-onset, resolves following cancer resection, and appears to be associated with conventional risk factors for DM. New-onset DM in patients with PaC is likely induced by the tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395079      PMCID: PMC2323514          DOI: 10.1053/j.gastro.2008.01.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

1.  Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results.

Authors:  C A Seiler; M Wagner; T Bachmann; C A Redaelli; B Schmied; W Uhl; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2005-05       Impact factor: 6.939

2.  Correlation between pancreatic endocrine and exocrine function and characteristics of pancreatic endocrine function in patients with diabetes mellitus owing to chronic pancreatitis.

Authors:  T Nakamura; K Imamura; K Takebe; A Terada; Y Arai; Y Tandoh; N Yamada; M Ishii; K Machida; T Suda
Journal:  Int J Pancreatol       Date:  1996-12

3.  The disease burden associated with overweight and obesity.

Authors:  A Must; J Spadano; E H Coakley; A E Field; G Colditz; W H Dietz
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

Review 4.  Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy.

Authors:  A Noy; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

5.  Clinical and hormonal aspects of pancreatic diabetes.

Authors:  S Bank; I N Marks; A I Vinik
Journal:  Am J Gastroenterol       Date:  1975-07       Impact factor: 10.864

6.  Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

7.  Maternal age and screening for gestational diabetes: a population-based study.

Authors:  D R Coustan; C Nelson; M W Carpenter; S R Carr; L Rotondo; J A Widness
Journal:  Obstet Gynecol       Date:  1989-04       Impact factor: 7.661

8.  Diabetes mellitus in pancreatic cancer follow-up.

Authors:  P Fogar; C Pasquali; D Basso; C Sperti; M P Panozzo; G Tessari; F D'Angeli; G Del Favero; M Plebani
Journal:  Anticancer Res       Date:  1994 Nov-Dec       Impact factor: 2.480

9.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.

Authors:  R Huxley; A Ansary-Moghaddam; A Berrington de González; F Barzi; M Woodward
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

Review 10.  The relationship between diabetes and pancreatic cancer.

Authors:  Feng Wang; Margery Herrington; Jörgen Larsson; Johan Permert
Journal:  Mol Cancer       Date:  2003-01-06       Impact factor: 27.401

View more
  167 in total

1.  Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.

Authors:  Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins
Journal:  HPB (Oxford)       Date:  2012-01-19       Impact factor: 3.647

2.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

3.  Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Chong-Chong Gao; Xiao-Lan Xu; Fei Li; Ben-Gang Gong; Shuang Liu; Ye-Qing Cui; Hai-Chen Sun; Ping-Yong Xu; Ya-Min Zheng; Hua Jiang
Journal:  Tumour Biol       Date:  2015-12-18

4.  The Association of Recently Diagnosed Diabetes and Long-term Diabetes With Survival in Pancreatic Cancer Patients: A Pooled Analysis.

Authors:  Christie Y Jeon; Donghui Li; Sean Cleary; Rachael Stolzenberg-Solomon; Cristina Bosetti; Carlo La Vecchia; Miquel Porta; Adetunji T Toriola; Rayjean J Hung; Robert C Kurtz; Sara H Olson
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

5.  Pancreatic cancer-associated diabetes is an "exosomopathy".

Authors:  Murray Korc
Journal:  Clin Cancer Res       Date:  2015-02-02       Impact factor: 12.531

6.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

7.  Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

8.  Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer.

Authors:  Rahul Pannala; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Am J Gastroenterol       Date:  2009-06-09       Impact factor: 10.864

9.  Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study.

Authors:  Evan J Walker; Andrew H Ko; Elizabeth A Holly; Paige M Bracci
Journal:  Int J Cancer       Date:  2014-08-14       Impact factor: 7.396

10.  Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.

Authors:  Claire Jenkinson; Victoria L Elliott; Anthony Evans; Lucy Oldfield; Rosalind E Jenkins; Darragh P O'Brien; Sophia Apostolidou; Aleksandra Gentry-Maharaj; Evangelia-O Fourkala; Ian J Jacobs; Usha Menon; Trevor Cox; Fiona Campbell; Stephen P Pereira; David A Tuveson; B Kevin Park; William Greenhalf; Robert Sutton; John F Timms; John P Neoptolemos; Eithne Costello
Journal:  Clin Cancer Res       Date:  2015-11-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.